

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELIRA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Hopkins
Date of last notice	23 December 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	i. Vanhop Pty Ltd <Vanhop Super Fund A/C> - Director and beneficiary ii. Mr Richard Miles Hopkins & Ms Maya Maureen vanden Dreisen <Jesam A/C> - Beneficiary
Date of change	11 August 2020
No. of securities held prior to change	i. 700,000 ordinary shares i. 3,125,000 Class A performance rights i. 3,125,000 Class B performance rights ii. 3,125,000 Class A performance rights ii. 3,125,000 Class B performance rights ii. 5,000,000 unlisted options with an exercise price of \$0.10 each and expire on 19 February 2022 ii. 5,000,000 unlisted options with an exercise price of \$0.15 each and expire on 19 February 2022 ii. 5,000,000 unlisted options with an exercise price of \$0.20 each and expire on 19 February 2022 ii. 5,000,000 unlisted options with an exercise price of \$0.28 each, vesting on 16 October 2020 and expire on 19 February 2022 ii. 5,000,000 unlisted options with an exercise price of \$0.30 each, vesting on 16 October 2020 and expire on 19 February 2022

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Class	Ordinary Shares
Number acquired	1,000,000
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.05 per share
No. of securities held after change	<ul style="list-style-type: none"> i. 1,700,000 ordinary shares i. 3,125,000 Class A performance rights i. 3,125,000 Class B performance rights ii. 3,125,000 Class A performance rights ii. 3,125,000 Class B performance rights ii. 5,000,000 unlisted options with an exercise price of \$0.10 each, vesting immediately and expire on 19 February 2022 ii. 5,000,000 unlisted options with an exercise price of \$0.15 each, subject to vesting conditions vesting on 16 October 2019 and expire on 19 February 2022 ii. 5,000,000 unlisted options with an exercise price of \$0.20 each, subject to vesting conditions vesting on 16 October 2019 and expire on 19 February 2022 ii. 5,000,000 unlisted options with an exercise price of \$0.28 each, vesting on 16 October 2020 and expire on 19 February 2022 ii. 5,000,000 unlisted options with an exercise price of \$0.30 each, vesting on 16 October 2020 and expire on 19 February 2022
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in Placement as approved by shareholders on 21 July 2020.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELIRA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Oludare Odumosu
Date of last notice	2 January 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	11 August 2020
No. of securities held prior to change	A. 5,500,655 ordinary shares B. 17,558,328 Class A performance rights C. 17,558,328 Class B performance rights
Class	D. Unquoted options exercisable at \$0.10 on or before 11 August 2023. E. Unquoted options exercisable at \$0.15 on or before 11 August 2023 and subject to vesting conditions. F. Unquoted options exercisable at \$0.20 on or before 11 August 2023 and subject to vesting conditions. G. Unquoted options exercisable at \$0.28 on or before 11 August 2023 and subject to vesting conditions. H. Unquoted options exercisable at \$0.30 on or before 11 August 2023 and subject to vesting conditions.

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	D. 5,000,000 E. 5,000,000 F. 5,000,000 G. 5,000,000 H. 5,000,000
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil consideration - issued as part director services – refer to the Notice of the General Meeting held on 17 June 2020 for further details
No. of securities held after change	A. 5,500,655 ordinary shares B. 17,558,328 Class A performance rights C. 17,558,328 Class B performance rights D. 5,000,000 Unquoted options exercisable at \$0.10 on or before 11 August 2023. E. 5,000,000 Unquoted options exercisable at \$0.15 on or before 11 August 2023 and subject to vesting conditions. F. 5,000,000 Unquoted options exercisable at \$0.20 on or before 11 August 2023 and subject to vesting conditions. G. 5,000,000 Unquoted options exercisable at \$0.28 on or before 11 August 2023 and subject to vesting conditions. H. 5,000,000 Unquoted options exercisable at \$0.30 on or before 11 August 2023 and subject to vesting conditions.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	As approved by shareholders on 21 July 2020

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.